Revisiting Cell Screening To Find New Cancer Drug Combos
Evidence is slowly building of the potential of high-throughput screening of individual patient tumors to test their sensitivity and response to hundreds of combinations of cancer drugs, first in leukemia and hopefully for treating other cancers.
You may also be interested in...
Combination therapies are the cornerstone of oncology, but the development model has been slow to shift to early testing of combinations of investigational drugs. The CoNNCT initiative aims to accelerate clinical testing of novel-novel combinations, and in doing so provide benefits for biopharma, clinicians and the cancer patients they serve.
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.